Adverse Effects

Biomarkers

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head & Neck Cancer

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematologic Oncology

Hormone-related Cancers

Immunotherapy

Vaccines

Infection

Leukemia

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Lung Cancer

Hodgkin Lymphoma

Lymphoma

Melanoma

Mesothelioma

Neuroendocrine Tumors

Oncology

Pediatric Cancers

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Surgery

Thyroid Cancer

News

Clinical Topics

Global Bulletin

All News

Approval Alert

Media

2 Minute Drill

Around the Practice

Between the Lines

Breaking Barriers

Face Off

From All Angles

Meeting of the Minds

Morning Rounds

OncView

Podcasts

Readout 360

Training Academy

Treatment Algorithms with the Oncology Brothers

Conferences

Publications

All Journals

Editorial Board

For Authors

Year in Review

Events

Frontline Forum

Satellite Sessions

CME/CE

Resources

Contemporary Concepts

Awareness Month

Interactive Tools

Nurse Practitioners/Physician's Assistants

Partners

Career Center

Subscribe

Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Editorial

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Cancer Network

Facebook

LinkedIn

Spotlight

Around the Practice 

Journal

Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice

Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Clinical

Acute Myeloid Leukemia

Genitourinary Cancer

Gynecologic Cancer

Hematology

Skin Cancer

1rem

View

Treatment Sequencing Strategies in R/R Multiple Myeloma

Video Series

Treatment Options for Late-line R/R MM

Videos

A panel of experts on relapsed/refractory multiple myeloma review clinical trial data on novel therapies and drug combinations and discuss treatment decision-making and sequencing practices.

A panel of myeloma specialists review the case of a 67-year-old patient with multiple myeloma (MM) who received a bispecific antibody.

Clinical Scenario 1: A 67-Year-Old Man with Multiple Myeloma

Following the presentation of a case of a patient with multiple myeloma, the panel have a roundtable discussion on how to approach treatment. 

Treatment Options in Late-line R/R MM Patients

Focusing on treatment paradigms for patients with relapsed/refractory multiple myeloma, the expert panel discusses the role of BCMA-targeted bispecifics and how they might consider sequencing therapies.

Sequencing Options of Bispecifics in R/R MM

Thomas G. Martin, MD, reviews findings from a pooled analysis from MagnetisMM that evaluated elranatamab in patients with relapsed/refractory MM who received prior BCMA-directed therapies.

Pooled Analysis from MagnetisMM Studies

The panel discusses how they approach treatment selection and sequencing for patients with relapsed/refractory multiple myeloma.

Consideration in Treatment Selection and Sequencing in R/R MM

Shaji Kumar, MD, presents the case of a 70-year-old patient with relapsed/refractory multiple myeloma who received CAR T-cell therapy.

Clinical Scenario 2: A 70-Year-Old Male with R/R MM

Following the presentation of a case of a patient with relapsed/refractory multiple myeloma, the expert panel reviews treatment options.

Shaji Kumar, MD, reviews data from cohort C of CARTITUDE-2 and a real-world study evaluating ide-cel in patients with relapsed/refractory multiple myeloma.

Overview of CAR-T Sequencing Strategies in R/R MM

Experts on multiple myeloma outline current challenges in determining the optimal treatment strategy for patients with relapsed/refractory disease who are eligible for bispecifics and CAR T-cell therapy.

Challenges in Optimizing Sequencing

Future Clinical Trials: Sequencing Decisions for Bispecifics and CAR T-Cell Therapy

Challenges in Optimizing Sequencing Strategies in R/R MM

The panel concludes its discussion with key takeaways on unmet needs and evolving treatment paradigms in relapsed/refractory multiple myeloma.

Unmet Needs and Future Perspectives in Treatment Sequencing Strategies in R/R MM

Treatment Options for Late-line R/R MM

EP: 1.Clinical Scenario 1: A 67-Year-Old Man with Multiple Myeloma

EP: 2.Treatment Options in Late-line R/R MM Patients

EP: 3.Sequencing Options of Bispecifics in R/R MM

EP: 4.Pooled Analysis from MagnetisMM Studies

EP: 5.Consideration in Treatment Selection and Sequencing in R/R MM

EP: 6.Clinical Scenario 2: A 70-Year-Old Male with R/R MM

EP: 7.Treatment Options for Late-line R/R MM

EP: 8.Overview of CAR-T Sequencing Strategies in R/R MM

EP: 9.Challenges in Optimizing Sequencing

EP: 10.Future Clinical Trials: Sequencing Decisions for Bispecifics and CAR T-Cell Therapy

EP: 11.Challenges in Optimizing Sequencing Strategies in R/R MM

EP: 12.Unmet Needs and Future Perspectives in Treatment Sequencing Strategies in R/R MM

Newsletter